Literature DB >> 24343669

Targeted therapies: Juggling combinations--not the way forward.

Lisa Hutchinson.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24343669     DOI： 10.1038/nrclinonc.2013.238

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  2 in total

1.  Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.

Authors:  Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544

2.  Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.

Authors:  Brian I Rini; Joaquim Bellmunt; Jill Clancy; Kongming Wang; Andreas G Niethammer; Subramanian Hariharan; Bernard Escudier
Journal:  J Clin Oncol       Date:  2013-12-02       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.